Cilostazol for intermittent claudication

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Bedenis, Rachel ^a   Stewart, Marlene ^a   Cleanthis, Marcus ^b   Robless, Peter ^c   Mikhailidis, Dimitri P ^d   Stansby, Gerard ^e  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CILOSTAZOL; PENTOXIFYLLINE; PLACEBO; TETRAZOLE DERIVATIVE;

ABNORMAL FECES; ALL CAUSE MORTALITY; ANKLE BRACHIAL INDEX; ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; DIARRHEA; DIZZINESS; DOSE RESPONSE; HEADACHE; HEART INFARCTION; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; MORTALITY RATE; OUTCOME ASSESSMENT; PAIN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR DISEASE; AGED; META ANALYSIS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; WALKING;

AGED; HUMANS; INTERMITTENT CLAUDICATION; MIDDLE AGED; MYOCARDIAL INFARCTION; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TETRAZOLES; WALKING;

EID: 84965187422     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003748.pub4     Document Type: Review

References (69)

1. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Archives of Internal Medicine 1999;159(17):2041-50.
2. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-92-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
3. Brass EP, Cooper LT, Morgan RE, Hiatt WR. A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery 2012;55(2):381-9.
4. Lewis RJC. Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials 2011;12:134.
5. NCT00783081. Safety and efficacy of K-134 for the treatment of intermittent claudication. www.clinicaltrials.gov/ct2/show/NCT00783081 (accessed May 2014).
6. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98(7):678-86.
7. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-90-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
8. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. American Journal of Medicine 2000;109(7):523-30.
9. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-96-202. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
10. de Albuquerque RM, Virgini-Magalhães CE, Lencastre SF, Bottino DA, Bouskela E. Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. Angiology 2008;59(5):549-58.
11. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arteriosclerosis, Thrombosis, and Vascular Biology 1998;18(12):1942-7.
12. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-93-201. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
13. Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery 1998;27(2):267-74.
14. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-203. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
15. O'Donnell M, Badger SA, Sharif MA, Young IS, Lau LL, Lee B, et al. Randomised controlled trial assessing the effects of cilostazol on exercise-induced ischaemia-reperfusion in patients with peripheral arterial disease. Proceedings of the European Society for Vascular Surgery Annual Meeting; 2008 Sep 4-7; Nice, France. 2008:43.
16. O'Donnell ME, Badger SA, Makar RR, McEneny J, Young IS, Lau LL, et al. The effects of cilostazol on the attenuation of inflammatory response in patients with peripheral arterial disease. The Vascular Society of Great Britain & Ireland Yearbook 2007:49.
17. O'Donnell ME, Badger SA, Makar RR, Young IS, Lau LL, Lee B, et al. The effects of cilostazol in diabetic patients. The Vascular Society of Great Britain & Ireland Yearbook 2007:82.
18. O'Donnell ME, Badger SA, Sharif MA, Makar RR, McEneny J, Young IS, et al. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. European Journal of Vascular and Endovascular Surgery 2009;37(3):326-35.
19. O'Donnell ME, Badger SA, Sharif MA, Makar RR, Young IS, Lee B, et al. The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. Angiology 2008;59(6):695-704.
20. O'Donnell ME, Badger SA, Sharif MA, Makar RR, Young IS, Lee B, et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vascular and Endovascular Surgery 2009;43(2):132-43.
21. O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. Journal of Vascular Surgery 2009;49(5):1226-34.
22. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
23. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-86-103. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
24. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-87-101. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
25. Otsuka America. Pletal (Cilostazol) Tablets. Study 21-94-301. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
26. Otsuka 21-95-201. A randomised double-blind study of the safety and efficacy of two different doses of cilostazol versus placebo in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
27. Anon. Pletal (cilostazol). Study 21-98-213 PACE. Otsuka Pharmaceuticals Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease 2010.
28. European Medicines Agency. Assessment report for Cilostazol containing medicinal products. European Medicines Agency 2013.
29. Otsuka 21-94-201. A randomised double blind study of the effect of cilostazol versus placebo on walking distances in patients with intermittent claudication secondary to peripheral vascular disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
30. Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery 2002;36(2):83-91.
31. NCT00443287. Efficacy and safety of HMR1766 in patients with Fontaine Stage ii peripheral arterial disease. www.clinicaltrials.gov/ct2/show/NCT00443287 (accessed May 2014).
32. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A study in long-term effects). Journal of Vascular Surgery 2008;47(2):330-6.
33. Otsuka 21-98-214-01. CASTLE. A randomized, double-blind, placebo-controlled, multicenter, parallel-arm, study to assess the long-term effects of Pletal® (Cilostazol) versus placebo administered orally to patients with intermittent claudication secondary to peripheral arterial disease. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
34. Stone WM, Demaerschalk BM, Fowl RJ, Money SR. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. Journal of Stroke and Cerebrovascular Diseases 2008;17(3):129-33.
35. Stone WM, Fowl RJ, Money SR. Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. Proceedings of the Vascular Annual Meeting; 2007 Jun 6-10; Baltimore. 2007.
36. Hsieh CJ, Wang PW. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Circulation Journal 2009;73(5):948-54.
37. Kim NH, Kim HY, An H, Seo JA, Kim NH, Choi KM, et al. Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: A randomised, double-blind, placebo-controlled, crossover trial. Diabetology and Metabolic Syndrome 2013;5(1):41.
38. NCT00300339. MASCOT: Mixed antagonist of serotonin for claudication optimal therapy. www.clinicaltrials.gov/ct2/show/NCT00300339?term=MASCOT&rank=2 (accessed May 2014).
39. Otsuka America. Pletal (Cilostazol) Tablets. Study PUIC-1. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
40. Otsuka America. Pletal (Cilostazol) Tablets. Study PUIC-2. www.accessdata.fda.gov/drugsatfda_docs/nda/99/20863.cfm (accessed May 2014).
41. Samra SS, Bajaj P, Vijayaraghavan KS, Potdar NP, Vyas D, Devani RG, et al. Efficacy and safety of cilostazol, a novel phosphodiesterase inhibitor in patients with intermittent claudication. Journal of the Indian Medical Association 2003;101(9):561-4.
42. NCT01188824. The safety and efficacy of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD study). clinicaltrials.gov/ct2/show/NCT01188824?term=SPAD&rank=3 (accessed May 2014).
43. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71-86.
44. Barnett AH, Bradbury AW, Brittenden J, Crichton B, Donnelly R, Homer-Vanniasinkam S, et al. The role of cilostazol in the treatment of intermittent claudication. Current Medical Research and Opinion 2004;20(10):1661-70.
45. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. American Journal of Cardiovascular Drugs 2003;3(2):117-38.
46. Dawson DL. Comparative effects of cilostazol and other therapies for intermittent claudication. American Journal of Cardiology 2001;87(12A):19D-27D.
47. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Seminars in Vascular Surgery 1999;12(2):123-37.
48. Fowkes FG, Gillespie IN. Angioplasty (versus non surgical management) for intermittent claudication. Cochrane Database of Systematic Reviews 1998, Issue 2. [DOI: 10.1002/14651858.CD000017]
49. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
50. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. Journal of Vascular Surgery 2008;48(1):144-9.
51. Khan S, Cleanthis M, Smout J, Flather M, Stansby G. Life-style modification in peripheral arterial disease. European Journal of Vascular and Endovascular Surgery 2005;29(1):2-9.
52. Lee S-W, Ahn J-M, Han S, Park G-M, Cho Y-R, Lee W-S, et al. Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials). American Journal of Cardiology 2013;112(9):1328-34.
53. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral artery disease in the general population. International Journal of Epidemiology 1996;25(6):1172-81.
54. National Institute for Health and Care Excellence (NICE). Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. www.nice.org.uk/guidance/TA223/chapter/2-Clinical-need-and-practice (accessed 11 July 2014).
55. National Institute for Health and Care Excellence (NICE). Lower limb peripheral arterial disease: diagnosis and management. www.nice.org.uk/Guidance/CG147 (accessed 11 July 2014).
56. Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. European Journal of Vascular and Endovascular Surgery 2003;26(1):1-16.
57. Pratt CM. Analysis of the cilostazol safety database. American Journal of Cardiology 2001;87(12A):28D-33D.
58. Regensteiner JG, Ware JE Jr, McCarthy WJ, Zhang P, Forbes WP, Heckman J, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. Journal of the American Geriatrics Society 2002;50(12):1939-46.
59. Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. Expert Opinion on Pharmacotherapy 2011;12(4):647-55.
60. Robless P, Mikhailidis D, Stansby G. Systematic review of antiplatelet therapy for prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. British Journal of Surgery 2001;88(6):787-800.
61. Sallustio F, Rotondo F, Di Legge S, Stanzione P. Cilostazol in the management of atherosclerosis. Current Vascular Pharmacology 2010;8(3):363-72.
62. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Technology Assessment Report commissioned by the NIHR HTA Programme on behalf of the National Institute for Health and Clinical Excellence. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for intermittent claudication in people with peripheral arterial disease. www.guidance.nice.org.uk/nicemedia/live/12265/51580/51580.pdf (accessed May 2014).
63. Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technology Assessment 2011;15(40):1-210. [DOI: 10.3310/hta15400]
64. Stevens JW, Simpson E, Harnan S, Squires H, Meng Y, Thomas S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. British Journal of Surgery 2012;99(12):1630-8.
65. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. American Journal of Cardiology 2002;90(12):1314-9.
66. Ueno H, Koyama H, Mima Y, Fukumoto S, Tanaka S, Shoji T, et al. Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. Journal of Atherosclerosis and Thrombosis 2011;18(10):883-90.
67. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD000990.pub2]
68. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD003748.pub2]
69. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD003748.pub3]